Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Revenue | $1,768 | $1,200 | $1,086 | $493 |
| % Growth | 47.3% | 10.5% | 120.2% | – |
| Cost of Goods Sold | $19 | $43 | $14 | $19 |
| Gross Profit | $1,749 | $1,157 | $1,073 | $474 |
| % Margin | 98.9% | 96.4% | 98.7% | 96.1% |
| R&D Expenses | $6,590 | $4,109 | $6,136 | $4,026 |
| G&A Expenses | $312 | $240 | $778 | $196 |
| SG&A Expenses | $2,300 | $1,739 | $1,387 | $1,667 |
| Sales & Mktg Exp. | $741 | $635 | $573 | $750 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,890 | $5,898 | $7,561 | $5,743 |
| Operating Income | -$7,141 | -$4,739 | -$6,499 | -$5,267 |
| % Margin | -403.9% | -394.9% | -598.1% | -1,067.5% |
| Other Income/Exp. Net | -$35 | -$4 | $392 | -$6 |
| Pre-Tax Income | -$7,176 | -$4,743 | -$6,107 | -$5,273 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,176 | -$4,743 | -$6,107 | -$5,273 |
| % Margin | -405.9% | -395.2% | -562.1% | -1,068.8% |
| EPS | -0.007 | -0.007 | -0.009 | -0.008 |
| % Growth | -6.1% | 28.3% | -17.9% | – |
| EPS Diluted | -0.007 | -0.007 | -0.009 | -0.008 |
| Weighted Avg Shares Out | 1,038,480 | 718,685 | 668,862 | 667,652 |
| Weighted Avg Shares Out Dil | 1,038,183 | 724,112 | 668,846 | 668,846 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $381 | $5 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $6 | $7 | $6 |
| EBITDA | -$7,167 | -$4,733 | -$6,107 | -$5,261 |
| % Margin | -405.4% | -394.4% | -562.1% | -1,066.3% |